CAR-T

Bristol-Myers' CAR-T gets priority review, mid-August PDUFA date
Bristol-Myers' CAR-T gets priority review, mid-August PDUFA date
Fierce Biotech
Bristol-Myers Squibb
FDA
lisocabtagene maraleucel
priority review
CAR-T
Flag link:
Gilead closes in on second CAR-T approval in US
Gilead closes in on second CAR-T approval in US
Pharmaforum
FDA
Gilead Sciences
Kite Pharma
mantle cell lymphoma
CAR-T
Flag link:
CAR-T tackles multiple myeloma by using the target CD229 to kill cancer stem cells
CAR-T tackles multiple myeloma by using the target CD229 to kill cancer stem cells
Fierce Biotech
CAR-T
Multiple Myeloma
CD229
JNJ
Bluebird Bio
Flag link:
Scripps Research’s Calibr to Test “Switchable” CAR-T in Clinical Trial
Scripps Research’s Calibr to Test “Switchable” CAR-T in Clinical Trial
Xconomy
Scripps Research Institute
Calibr
CAR-T
Flag link:
MD Anderson emerges with strong evidence for natural killer cell therapy, and Takeda looks like a winner
MD Anderson emerges with strong evidence for natural killer cell therapy, and Takeda looks like a winner
Endpoints
Takeda
MD Anderson
natural killer cell therapy
CAR-T
Flag link:
Adaptimmune and Astellas to Co-Develop Allogenic CAR-T and TCR T-Cell Therapies
Adaptimmune and Astellas to Co-Develop Allogenic CAR-T and TCR T-Cell Therapies
BioSpace
Adaptimmune
SPEAR-T
Astellas
CAR-T
cell therapy
drug development
Flag link:
Merck-partnered biotech hands Roche its half-life extension tech as it pivots to immuno-oncology
Merck-partnered biotech hands Roche its half-life extension tech as it pivots to immuno-oncology
Endpoints
Roche
immuno-oncology
Amunix
Merck
CAR-T
Flag link:
Docs are excited about CAR-T, BTK drugs, survey finds. How can pharma best promote them?
Docs are excited about CAR-T, BTK drugs, survey finds. How can pharma best promote them?
Fierce Pharma
physicians
oncologists
Multiple Myeloma
CAR-T
Flag link:
Bristol-Myers unloads old-school plant as it readies for CAR-T future
Bristol-Myers unloads old-school plant as it readies for CAR-T future
Fierce Pharma
Bristol-Myers Squibb
Celgene
CAR-T
M&A
Flag link:
3 trends in biotech to watch in 2020
3 trends in biotech to watch in 2020
Stat
IPOs
eteplirsen
CAR-T
gene therapy
cell therapy
biotech
Flag link:
Pharma's gene and cell therapy ambitions will kick into high gear in 2020—despite some major hurdles
Pharma's gene and cell therapy ambitions will kick into high gear in 2020—despite some major hurdles
Fierce Pharma
gene therapy
reimbursement
drug manufacturing
Bristol-Myers Squibb
Pfizer
Biomarin
Sarepta Therapeutics
Gilead Sciences
CAR-T
Flag link:
Anixa delays CAR-T trial in bid to boost efficacy
Anixa delays CAR-T trial in bid to boost efficacy
Fierce Biotech
Anixa Biosciences
ovarian cancer
CAR-T
Flag link:
Gilead's Kite files for FDA approval of second CAR-T therapy
Gilead's Kite files for FDA approval of second CAR-T therapy
Fierce Biotech
Gilead Sciences
KTE-X19
mantle cell lymphoma
CAR-T
Kite Pharma
Flag link:
Novartis still hasn't solved its lingering CAR-T manufacturing issues
Novartis still hasn't solved its lingering CAR-T manufacturing issues
Biopharma Dive
ASH2019
Novartis
FDA
CAR-T
drug manufacturing
Kymriah
Flag link:
Novartis Kymriah demonstrates consistent efficacy and safety outcomes in US patients when used in real-world setting
Novartis Kymriah demonstrates consistent efficacy and safety outcomes in US patients when used in real-world setting
Pharmaceutical Business Review
Novartis
Kymriah
CAR-T
DLBCL
ALL
Flag link:
ASH: Gilead touts 'astounding' Yescarta survival results at 3 years
ASH: Gilead touts 'astounding' Yescarta survival results at 3 years
Fierce Pharma
Gilead Sciences
Yescarta
ASH2019
CAR-T
refractory large B-cell lymphoma
Flag link:
2 Small-Cap Biotechs That Soared Last Week
2 Small-Cap Biotechs That Soared Last Week
Motley Fool
Magenta Therapeutics
Molecular Templates
gene therapy
CAR-T
cancer
Flag link:
Celgene posts pivotal CAR-T data ahead of FDA filing
Celgene posts pivotal CAR-T data ahead of FDA filing
Fierce Biotech
Celgene
CAR-T
liso-cel
Kymriah
Yescarta
Flag link:
CAR-T cells as 'bait' show promise in autoimmune disease
CAR-T cells as 'bait' show promise in autoimmune disease
Fierce Biotech
CAR-T
autoimmune disease
Flag link:
Italian gene therapy player draws new investor from China for its answer to CAR-T relapses
Italian gene therapy player draws new investor from China for its answer to CAR-T relapses
Endpoints
gene therapy
Genenta Science
clinical trials
glioblastoma
Multiple Myeloma
CAR-T
Flag link:

Pages